Cargando…

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Myelodysplastic syndrome (MDS) defines a group of heterogeneous hematologic malignancies that often progresses to acute myeloid leukemia (AML). The leading treatment for high-risk MDS patients is azacitidine (Aza, Vidaza(®)), but a significant proportion of patients are refractory and all patients e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cluzeau, Thomas, Furstoss, Nathan, Savy, Coline, El Manaa, Wejdane, Zerhouni, Marwa, Blot, Lauriane, Calleja, Anne, Dufies, Maeva, Dubois, Alix, Ginet, Clemence, Mounier, Nicolas, Garnier, Georges, Raynaud, Sophie, Rohrlich, Pierre Simon, Peterlin, Pierre, Stamatoullas, Aspasia, Chermat, Fatiha, Fenaux, Pierre, Jacquel, Arnaud, Robert, Guillaume, Auberger, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981810/ https://www.ncbi.nlm.nih.gov/pubmed/31881723 http://dx.doi.org/10.3390/ijms21010164

Ejemplares similares

Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines
por: Cluzeau, Thomas, et al.
Publicado: (2014)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
por: Cluzeau, Thomas, et al.
Publicado: (2012)

Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML
por: Dubois, Alix, et al.
Publicado: (2020)

ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines
por: Dufies, Maeva, et al.
Publicado: (2017)

Reprogramming monocyte-derived macrophages through caspase inhibition
por: Chaintreuil, Paul, et al.
Publicado: (2021)

Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death
por: Dubois, Alix, et al.
Publicado: (2016)

Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells
por: Dufies, Maeva, et al.
Publicado: (2011)

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia
por: Vidal, Valérie, et al.
Publicado: (2017)

Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death
por: Robert, Guillaume, et al.
Publicado: (2009)

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
por: Cluzeau, Thomas, et al.
Publicado: (2021)

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
por: Sébert, Marie, et al.
Publicado: (2019)

The generation, activation, and polarization of monocyte-derived macrophages in human malignancies
por: Chaintreuil, Paul, et al.
Publicado: (2023)

Acadesine Triggers Non-apoptotic Death in Tumor Cells
por: Glazunova, V. A., et al.
Publicado: (2013)

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway
por: Robert, Guillaume, et al.
Publicado: (2012)

Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine
por: Cluzeau, T, et al.
Publicado: (2013)

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
por: Van Den Neste, Eric, et al.
Publicado: (2012)

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Loschi, Michael, et al.
Publicado: (2022)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib
por: Cassuto, Ophélie, et al.
Publicado: (2012)

Bcl-2(high) mantle cell lymphoma cells are sensitized to acadesine with ABT-199
por: Montraveta, Arnau, et al.
Publicado: (2015)

Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma
por: Pinochet, Pierre, et al.
Publicado: (2021)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes
por: Cluzeau, Thomas, et al.
Publicado: (2017)

Circumventing the Greatwall
por: Short, Ben
Publicado: (2014)

Chaperone-Mediated Autophagy and Its Emerging Role in Hematological Malignancies
por: Robert, Guillaume, et al.
Publicado: (2019)

Synthesis of New Acadesine (AICA-riboside) Analogues Having Acyclic d-ribityl or 4-Hydroxybutyl Chains in Place of the Ribose
por: D’Errico, Stefano, et al.
Publicado: (2013)

Acadesine suppresses TNF-α induced complement component 3 (C3), in retinal pigment epithelial (RPE) cells
por: Efstathiou, Nikolaos E., et al.
Publicado: (2020)

Real‐life challenges using personalized prognostic scoring systems in acute myeloid leukemia
por: Calleja, Anne, et al.
Publicado: (2022)

The Endoplasmic Reticulum Stress/Unfolded Protein Response and Their Contributions to Parkinson’s Disease Physiopathology
por: da Costa, Cristine Alves, et al.
Publicado: (2020)

A critical assessment of interatomic potentials for modelling lattice defects in forsterite Mg[Formula: see text] SiO[Formula: see text] from 0 to 12 GPa
por: Hirel, Pierre, et al.
Publicado: (2021)

Implication and Regulation of AMPK during Physiological and Pathological Myeloid Differentiation
por: Jacquel, Arnaud, et al.
Publicado: (2018)

Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma
por: Montraveta, Arnau, et al.
Publicado: (2014)

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies
por: Ades, Lionel, et al.
Publicado: (2017)

Re: Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients
por: Raynaud, Jean-Sébastien, et al.
Publicado: (2018)

IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential
por: Boulakirba, Sonia, et al.
Publicado: (2018)

Strategies to circumvent the CFTR defect in cystic fibrosis
por: Becq, Frédéric, et al.
Publicado: (2013)

Designing malaria vaccines to circumvent antigen variability()
por: Ouattara, Amed, et al.
Publicado: (2015)

How Dengue Virus Circumvents Innate Immunity
por: Kao, Yu-Ting, et al.
Publicado: (2018)

Potential mechanisms of resistance to venetoclax and strategies to circumvent it
por: Tahir, Stephen K., et al.
Publicado: (2017)

PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY
por: de Botton, Stéphane, et al.
Publicado: (2023)

Network Connections That Evolve to Circumvent the Inverse Optics Problem
por: Ng, Cherlyn, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_laahelqbe1ohgkobi51v25kcqn